Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Sax

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Current Opinion in HIV and AIDS|January 10, 2012
Treatment-for-prevention: clinical considerationsShahin Lockman, Paul Sax
AIDS Patient Care and Stds|June 21, 2003
Current management challenges in HIV: tolerability of antiretrovirals and metabolic complicationsCharles Hicks, Judith Currier, Paul Sax, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 24, 2019
Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety AnalysisMelanie Thompson, Chloe Orkin, Jean-Michel Molina, et al.
Cell Reports|December 21, 2017
Transcriptional Changes during Naturally Acquired Zika Virus Infection Render Dendritic Cells Highly Conducive to Viral ReplicationXiaoming Sun, Stephane Hua, Hsiao-Rong Chen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2013
Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabineKimberly Y Smith, Camlin Tierney, Katie Mollan, et al.
Antiviral Therapy|August 30, 2013
Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) studyDavid A Wohl, Gretchen Arnoczy, Carl J Fichtenbaum, et al.
Infection & Chemotherapy|October 6, 2016
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub-Analysis of Phase 3 Clinical TrialsJun Yong Choi, Somnuek Sungkanuparph, Thanomsak Anekthananon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 13, 2026
Hypertension in a randomized trial of dolutegravir- versus efavirenz-based antiretroviral therapy in pregnant and postpartum women with HIVRisa Hoffman, Sean Brummel, Mauricio Pinilla, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 5, 2024
Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and PostpartumRisa M Hoffman, Sean Brummel, Lauren Ziemba, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Current Opinion in HIV and AIDS|January 10, 2012
Treatment-for-prevention: clinical considerationsShahin Lockman, Paul Sax
AIDS Patient Care and Stds|June 21, 2003
Current management challenges in HIV: tolerability of antiretrovirals and metabolic complicationsCharles Hicks, Judith Currier, Paul Sax, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 24, 2019
Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety AnalysisMelanie Thompson, Chloe Orkin, Jean-Michel Molina, et al.
Cell Reports|December 21, 2017
Transcriptional Changes during Naturally Acquired Zika Virus Infection Render Dendritic Cells Highly Conducive to Viral ReplicationXiaoming Sun, Stephane Hua, Hsiao-Rong Chen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2013
Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabineKimberly Y Smith, Camlin Tierney, Katie Mollan, et al.
Antiviral Therapy|August 30, 2013
Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) studyDavid A Wohl, Gretchen Arnoczy, Carl J Fichtenbaum, et al.
Infection & Chemotherapy|October 6, 2016
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub-Analysis of Phase 3 Clinical TrialsJun Yong Choi, Somnuek Sungkanuparph, Thanomsak Anekthananon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 13, 2026
Hypertension in a randomized trial of dolutegravir- versus efavirenz-based antiretroviral therapy in pregnant and postpartum women with HIVRisa Hoffman, Sean Brummel, Mauricio Pinilla, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 5, 2024
Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and PostpartumRisa M Hoffman, Sean Brummel, Lauren Ziemba, et al.
Pageof 1